Document ID: chunk:federal_register_of_legislation:F2024C00867:reg:2
Version: federal_register_of_legislation:F2024C00867
Segment Type: reg
Provision Reference: reg 2
Character Range: 29602–31240

2                                                           for a therapeutic vaping substance or a therapeutic vaping substance accessory that contains nicotine—the word "nicotine" and the concentration of nicotine as follows:
                                                              (a) where the nicotine is in base form—the base form concentration of nicotine in mg/mL;
                                                              (b) where the nicotine is in single salt form—the equivalent base form concentration of nicotine in mg/mL, with the name of the salt form in brackets immediately after the word "nicotine";
                                                                    Example: For a therapeutic vaping substance containing 15 mg/mL of nicotine lactate, with an equivalent base form concentration of 10 mg/mL nicotine , the statement of concentration required to be on the main label is "nicotine (as lactate) 10 mg/mL".
                                                              (c) where the nicotine is a combination of salt forms or a combination of salt and base forms—the total equivalent base form concentration of nicotine in mg/mL, with the names of all the forms of nicotine in brackets immediately after the word "nicotine"
                                                                    Example: For a therapeutic vaping substance containing 5 mg/mL of nicotine as benzoate salt and 15 mg/mL nicotine lactate, with an equivalent base form concentration of 12 mg/mL nicotine , the statement of concentration required to be on the main label is "nicotine (as benzoate and lactate) 12 mg/mL".